- Home
- FRD vs SPRO Comparison
FRD vs SPRO Comparison
Compare FRD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- SPRO
- Stock Information
- Founded
- FRD 1965
- SPRO 2013
- Country
- FRD United States
- SPRO United States
- Employees
- FRD N/A
- SPRO N/A
- Industry
- FRD Steel/Iron Ore
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- FRD Industrials
- SPRO Health Care
- Exchange
- FRD Nasdaq
- SPRO Nasdaq
- Market Cap
- FRD 114.4M
- SPRO 121.0M
- IPO Year
- FRD N/A
- SPRO 2017
- Fundamental
- Price
- FRD $21.13
- SPRO $1.90
- Analyst Decision
- FRD
- SPRO Buy
- Analyst Count
- FRD 0
- SPRO 4
- Target Price
- FRD N/A
- SPRO $5.00
- AVG Volume (30 Days)
- FRD 30.5K
- SPRO 398.1K
- Earning Date
- FRD 11-11-2025
- SPRO 11-13-2025
- Dividend Yield
- FRD 0.76%
- SPRO N/A
- EPS Growth
- FRD N/A
- SPRO N/A
- EPS
- FRD 1.21
- SPRO N/A
- Revenue
- FRD $464,826,000.00
- SPRO $48,576,000.00
- Revenue This Year
- FRD N/A
- SPRO N/A
- Revenue Next Year
- FRD N/A
- SPRO N/A
- P/E Ratio
- FRD $17.44
- SPRO N/A
- Revenue Growth
- FRD N/A
- SPRO N/A
- 52 Week Low
- FRD $12.24
- SPRO $0.51
- 52 Week High
- FRD $22.96
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- FRD 64.00
- SPRO 39.50
- Support Level
- FRD $21.04
- SPRO $1.91
- Resistance Level
- FRD $22.96
- SPRO $2.18
- Average True Range (ATR)
- FRD 0.90
- SPRO 0.10
- MACD
- FRD 0.09
- SPRO 0.01
- Stochastic Oscillator
- FRD 65.14
- SPRO 19.18
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.